Juan Miguel Mosquera is a Board Certified Pathologist in Anatomic and Clinical Pathology, with expertise in genitourinary pathology and interest in soft tissue pathology and molecular genomics.
He is Associate Professor in the Department of Pathology and Laboratory Medicine and Co-Chief of Genitourinary Pathology. His research endeavors revolve around the development and validation of tissue-based biomarkers with an emphasis on prostate cancer.
During his fellowship, Dr. Mosquera led projects that highlighted clinical relevance of TMPRSS2-ERG gene fusion in prostate cancer and high-grade prostatic intraepithelial neoplasia.
Since then, he has achieved expertise in the development of biomarkers using fluorescence and chromogenic in situ hybridization (ISH) (Diagn Mol Pathol 2011).
This effort has translated in tissue-based validation assays in studies from the Early Detection Research Network (EDRN), the Cancer Genome Atlas (TCGA) and other multi-institutional studies (Prostate Cancer P D 2013; Nature 2013).
Most recently, Dr. Mosquera has significantly contributed to the discovery of ERF, a new prostate cancer tumor suppressor gene in African Americans.
Dr. Mosquera has also led new discoveries of disease-defining gene fusions through RNA sequencing of rare soft tissue tumors, in collaboration with investigators at Weill Cornell and Memorial Sloan Kettering Cancer Center (MSKCC).
As Pathology Team Leader of the Caryl and Israel Englander Institute for Precision Medicine, Dr. Mosquera has the responsibility to oversee development of in situ assays and to supervise all pathology related protocols.